Metyrapone, an inhibitor of glucocorticoid production, reduces brain injury induced by focal and global ischemia and seizures

Virginia L. Smith-Swintosky, L. Creed Pettigrew, Robert M. Sapolsky, Chris Phares, Susan D. Craddock, Sheila M. Brooke, Mark P. Mattson

Research output: Contribution to journalArticle

Abstract

Increasing evidence indicates that glucocorticoids (GCs), produced in response to physical/emotional stressors, can exacerbate brain damage resulting from cerebral ischemia and severe seizure activity. However, much of the supporting evidence has come from studies employing nonphysiological paradigms in which adrenalectomized rats were compared with those exposed to constant GC concentrations in the upper physiological range. Cerebral ischemia and seizures can induce considerable GC secretion. We now present data from experiments using metyrapone (an 11-β-hydroxylase inhibitor of GC production), which demonstrate that the GC stress-response worsens subsequent brain damage induced by ischemia and seizures in rats. Three different paradigms of brain injury were employed: middle cerebral artery occlusion (MCAO) model of focal cerebral ischemia; four-vessel occlusion (4VO) model of transient global forebrain ischemia; and kainic acid (KA)-induced (seizure- mediated) excitotoxic damage to hippocampal CA3 and CA1 neurons. Metyrapone (200 mg/kg body wt) was administered systemically in a single i.p. bolus 30 min prior to each insult. In the MCAO model, metyrapone treatment significantly reduced infarct volume and also preserved cells within the infarct. In the 4VO model, neuronal loss in region CA1 of the hippocampus was significantly reduced in rats administered metyrapone. Seizure-induced damage to hippocampal pyramidal neurons (assessed by cell counts and immunochemical analyses of cytoskeletal alterations) was significantly reduced in rats administered metyrapone. Measurement of plasma levels of corticosterone (the species-typical GC of rats) after each insult showed that metyrapone significantly suppressed the injury-induced rise in levels of circulating corticosterone. These findings indicate that endogenous corticosterone contributes to the basal level of brain injury resulting from cerebral ischemia and excitotoxic seizure activity and suggest that drugs that suppress glucocorticoid production may be effective in reducing brain damage in stroke and epilepsy patients.

Original languageEnglish (US)
Pages (from-to)585-598
Number of pages14
JournalJournal of Cerebral Blood Flow and Metabolism
Volume16
Issue number4
StatePublished - 1996
Externally publishedYes

Fingerprint

Metyrapone
Brain Injuries
Glucocorticoids
Seizures
Ischemia
Brain Ischemia
Corticosterone
Middle Cerebral Artery Infarction
Brain
Pyramidal Cells
Kainic Acid
Prosencephalon
Mixed Function Oxygenases
Epilepsy
Hippocampus
Cell Count
Stroke
Neurons
Wounds and Injuries
Pharmaceutical Preparations

Keywords

  • Alzheimer's
  • Corticosterone
  • Excitotoxicity
  • Hippocampus
  • Kainic acid
  • Microtubule-associated proteins
  • Middle cerebral artery occlusion
  • Transient global forebrain ischemia

ASJC Scopus subject areas

  • Endocrinology
  • Neuroscience(all)
  • Endocrinology, Diabetes and Metabolism

Cite this

Smith-Swintosky, V. L., Pettigrew, L. C., Sapolsky, R. M., Phares, C., Craddock, S. D., Brooke, S. M., & Mattson, M. P. (1996). Metyrapone, an inhibitor of glucocorticoid production, reduces brain injury induced by focal and global ischemia and seizures. Journal of Cerebral Blood Flow and Metabolism, 16(4), 585-598.

Metyrapone, an inhibitor of glucocorticoid production, reduces brain injury induced by focal and global ischemia and seizures. / Smith-Swintosky, Virginia L.; Pettigrew, L. Creed; Sapolsky, Robert M.; Phares, Chris; Craddock, Susan D.; Brooke, Sheila M.; Mattson, Mark P.

In: Journal of Cerebral Blood Flow and Metabolism, Vol. 16, No. 4, 1996, p. 585-598.

Research output: Contribution to journalArticle

Smith-Swintosky, VL, Pettigrew, LC, Sapolsky, RM, Phares, C, Craddock, SD, Brooke, SM & Mattson, MP 1996, 'Metyrapone, an inhibitor of glucocorticoid production, reduces brain injury induced by focal and global ischemia and seizures', Journal of Cerebral Blood Flow and Metabolism, vol. 16, no. 4, pp. 585-598.
Smith-Swintosky, Virginia L. ; Pettigrew, L. Creed ; Sapolsky, Robert M. ; Phares, Chris ; Craddock, Susan D. ; Brooke, Sheila M. ; Mattson, Mark P. / Metyrapone, an inhibitor of glucocorticoid production, reduces brain injury induced by focal and global ischemia and seizures. In: Journal of Cerebral Blood Flow and Metabolism. 1996 ; Vol. 16, No. 4. pp. 585-598.
@article{d48eec153ac84b06870bb7f2e6fe7536,
title = "Metyrapone, an inhibitor of glucocorticoid production, reduces brain injury induced by focal and global ischemia and seizures",
abstract = "Increasing evidence indicates that glucocorticoids (GCs), produced in response to physical/emotional stressors, can exacerbate brain damage resulting from cerebral ischemia and severe seizure activity. However, much of the supporting evidence has come from studies employing nonphysiological paradigms in which adrenalectomized rats were compared with those exposed to constant GC concentrations in the upper physiological range. Cerebral ischemia and seizures can induce considerable GC secretion. We now present data from experiments using metyrapone (an 11-β-hydroxylase inhibitor of GC production), which demonstrate that the GC stress-response worsens subsequent brain damage induced by ischemia and seizures in rats. Three different paradigms of brain injury were employed: middle cerebral artery occlusion (MCAO) model of focal cerebral ischemia; four-vessel occlusion (4VO) model of transient global forebrain ischemia; and kainic acid (KA)-induced (seizure- mediated) excitotoxic damage to hippocampal CA3 and CA1 neurons. Metyrapone (200 mg/kg body wt) was administered systemically in a single i.p. bolus 30 min prior to each insult. In the MCAO model, metyrapone treatment significantly reduced infarct volume and also preserved cells within the infarct. In the 4VO model, neuronal loss in region CA1 of the hippocampus was significantly reduced in rats administered metyrapone. Seizure-induced damage to hippocampal pyramidal neurons (assessed by cell counts and immunochemical analyses of cytoskeletal alterations) was significantly reduced in rats administered metyrapone. Measurement of plasma levels of corticosterone (the species-typical GC of rats) after each insult showed that metyrapone significantly suppressed the injury-induced rise in levels of circulating corticosterone. These findings indicate that endogenous corticosterone contributes to the basal level of brain injury resulting from cerebral ischemia and excitotoxic seizure activity and suggest that drugs that suppress glucocorticoid production may be effective in reducing brain damage in stroke and epilepsy patients.",
keywords = "Alzheimer's, Corticosterone, Excitotoxicity, Hippocampus, Kainic acid, Microtubule-associated proteins, Middle cerebral artery occlusion, Transient global forebrain ischemia",
author = "Smith-Swintosky, {Virginia L.} and Pettigrew, {L. Creed} and Sapolsky, {Robert M.} and Chris Phares and Craddock, {Susan D.} and Brooke, {Sheila M.} and Mattson, {Mark P.}",
year = "1996",
language = "English (US)",
volume = "16",
pages = "585--598",
journal = "Journal of Cerebral Blood Flow and Metabolism",
issn = "0271-678X",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Metyrapone, an inhibitor of glucocorticoid production, reduces brain injury induced by focal and global ischemia and seizures

AU - Smith-Swintosky, Virginia L.

AU - Pettigrew, L. Creed

AU - Sapolsky, Robert M.

AU - Phares, Chris

AU - Craddock, Susan D.

AU - Brooke, Sheila M.

AU - Mattson, Mark P.

PY - 1996

Y1 - 1996

N2 - Increasing evidence indicates that glucocorticoids (GCs), produced in response to physical/emotional stressors, can exacerbate brain damage resulting from cerebral ischemia and severe seizure activity. However, much of the supporting evidence has come from studies employing nonphysiological paradigms in which adrenalectomized rats were compared with those exposed to constant GC concentrations in the upper physiological range. Cerebral ischemia and seizures can induce considerable GC secretion. We now present data from experiments using metyrapone (an 11-β-hydroxylase inhibitor of GC production), which demonstrate that the GC stress-response worsens subsequent brain damage induced by ischemia and seizures in rats. Three different paradigms of brain injury were employed: middle cerebral artery occlusion (MCAO) model of focal cerebral ischemia; four-vessel occlusion (4VO) model of transient global forebrain ischemia; and kainic acid (KA)-induced (seizure- mediated) excitotoxic damage to hippocampal CA3 and CA1 neurons. Metyrapone (200 mg/kg body wt) was administered systemically in a single i.p. bolus 30 min prior to each insult. In the MCAO model, metyrapone treatment significantly reduced infarct volume and also preserved cells within the infarct. In the 4VO model, neuronal loss in region CA1 of the hippocampus was significantly reduced in rats administered metyrapone. Seizure-induced damage to hippocampal pyramidal neurons (assessed by cell counts and immunochemical analyses of cytoskeletal alterations) was significantly reduced in rats administered metyrapone. Measurement of plasma levels of corticosterone (the species-typical GC of rats) after each insult showed that metyrapone significantly suppressed the injury-induced rise in levels of circulating corticosterone. These findings indicate that endogenous corticosterone contributes to the basal level of brain injury resulting from cerebral ischemia and excitotoxic seizure activity and suggest that drugs that suppress glucocorticoid production may be effective in reducing brain damage in stroke and epilepsy patients.

AB - Increasing evidence indicates that glucocorticoids (GCs), produced in response to physical/emotional stressors, can exacerbate brain damage resulting from cerebral ischemia and severe seizure activity. However, much of the supporting evidence has come from studies employing nonphysiological paradigms in which adrenalectomized rats were compared with those exposed to constant GC concentrations in the upper physiological range. Cerebral ischemia and seizures can induce considerable GC secretion. We now present data from experiments using metyrapone (an 11-β-hydroxylase inhibitor of GC production), which demonstrate that the GC stress-response worsens subsequent brain damage induced by ischemia and seizures in rats. Three different paradigms of brain injury were employed: middle cerebral artery occlusion (MCAO) model of focal cerebral ischemia; four-vessel occlusion (4VO) model of transient global forebrain ischemia; and kainic acid (KA)-induced (seizure- mediated) excitotoxic damage to hippocampal CA3 and CA1 neurons. Metyrapone (200 mg/kg body wt) was administered systemically in a single i.p. bolus 30 min prior to each insult. In the MCAO model, metyrapone treatment significantly reduced infarct volume and also preserved cells within the infarct. In the 4VO model, neuronal loss in region CA1 of the hippocampus was significantly reduced in rats administered metyrapone. Seizure-induced damage to hippocampal pyramidal neurons (assessed by cell counts and immunochemical analyses of cytoskeletal alterations) was significantly reduced in rats administered metyrapone. Measurement of plasma levels of corticosterone (the species-typical GC of rats) after each insult showed that metyrapone significantly suppressed the injury-induced rise in levels of circulating corticosterone. These findings indicate that endogenous corticosterone contributes to the basal level of brain injury resulting from cerebral ischemia and excitotoxic seizure activity and suggest that drugs that suppress glucocorticoid production may be effective in reducing brain damage in stroke and epilepsy patients.

KW - Alzheimer's

KW - Corticosterone

KW - Excitotoxicity

KW - Hippocampus

KW - Kainic acid

KW - Microtubule-associated proteins

KW - Middle cerebral artery occlusion

KW - Transient global forebrain ischemia

UR - http://www.scopus.com/inward/record.url?scp=0029946863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029946863&partnerID=8YFLogxK

M3 - Article

C2 - 8964797

AN - SCOPUS:0029946863

VL - 16

SP - 585

EP - 598

JO - Journal of Cerebral Blood Flow and Metabolism

JF - Journal of Cerebral Blood Flow and Metabolism

SN - 0271-678X

IS - 4

ER -